相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)
Eyad Elkord et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
T Cell-Based Immunotherapy of Metastatic Renal Cell Carcinoma: Modest Success and Future Perspective
Alaaeldin Shablak et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α
Robert E. Hawkins et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α) A Phase 2 Trial
Robert J. Amato et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
Howard L. Kaufman et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
Robert J. Amato et al.
CLINICAL CANCER RESEARCH (2008)
An MVA-based Vaccine Targeting the Oncofetal Antigen 5T4 in Patients Undergoing Surgical Resection of Colorectal Cancer Liver Metastases
Eyad Elkord et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses
Richard Harrop et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
CD4+ T-cell recognition of human 5T4 oncofoetal antigen:: implications for initial depletion of CD25+ T cells
Eyad Elkord et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Adoptive transfer of Treg depleted autologous T cells in advanced renal cell carcinoma
Fiona C. Thistlethwaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Epithelial-mesenchymal transition events during human embryonic stem cell differentiation
Angela M. Eastham et al.
CANCER RESEARCH (2007)
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
Richard W. Griffiths et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells
Helen L. Spencer et al.
MOLECULAR BIOLOGY OF THE CELL (2007)
Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses
Richard Harrop et al.
CLINICAL CANCER RESEARCH (2007)
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma
D. M. Shaw et al.
BRITISH JOURNAL OF CANCER (2007)
Immunotherapy of renal cell carcinoma
Cecile Gouttefangeas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Advanced renal cell carcinoma - current and emerging management strategies
Bernard Escudier
DRUGS (2007)
CD4+ CD25+ FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer
Sarah L. Clarke et al.
PLOS ONE (2006)
Immunotherapy for renal cell cancer
James C. Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CD8 T-cell recognition of human 5T4 oncofetal antigen
Lucy J. C. Smyth et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Epidemiologic aspects of renal cell carcinoma
Joseph K. McLaughlin et al.
SEMINARS IN ONCOLOGY (2006)
Cell surface 5T4 antigen is transiently upregulated during early human embryonic stem cell differentiation: Effect of 5T4 phenotype on neural lineage formation
Christopher M. Ward et al.
EXPERIMENTAL CELL RESEARCH (2006)
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial
Richard Harrop et al.
CLINICAL CANCER RESEARCH (2006)
Renal-cell carcinoma
HT Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Engineering T cells for cancer therapy
W Mansoor et al.
BRITISH JOURNAL OF CANCER (2005)
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
RW Griffiths et al.
BRITISH JOURNAL OF CANCER (2005)
Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose Control in PNU-214936
JD Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cell adhesion and signalling by cadherins and Ig-CAMs in cancer
U Cavallaro et al.
NATURE REVIEWS CANCER (2004)
Antigenic targets for renal cell carcinoma immunotherapy
J Vieweg et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2004)
The 5T4 oncofoetal antigen is an early differentiation marker of mouse ES cells and its absence is a useful means to assess pluripotency
CM Ward et al.
JOURNAL OF CELL SCIENCE (2003)
Identification of the antigenic epitopes in Staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy
E Erlandsson et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis
A Awan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
分享论文
